drugset
Drugs / RG002
last change 2 days ago re-read 3 minutes ago

RG002

Messenger RNA (mRNA)

Developed for
cervical intraepithelial neoplasia grade 2/3 · intraepithelial neoplasia
Investigated by
RinuaGene Biotechnology Co., Ltd.

Trials 1

today NCT06273553 · Ph 1/2
20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06273553 Mar 2024 → Oct 2026 expected cervical intraepithelial neoplasia grade 2/3, human papilloma virus infection, intraepithelial neoplasia RinuaGene Biotechnology Co., Ltd. Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2024-12-04 RinuaGene Biotechnology Co., Ltd. Regulatory RinuaGene's HPV Therapeutic mRNA Vaccine Received IND Clearance from China CDE rinuagene.com ↗
2024-05-16 RinuaGene Biotechnology Co., Ltd. Results Molecular Therapy | RinuaGene Published Early Research Data of HPV Therapeutic Vaccine rinuagene.com ↗
The early research data underscores RinuaGene's innovative design strategy for the mRNA therapeutic vaccine (RG002) targeting HPV-related diseases.
2023-11-06 RinuaGene Biotechnology Co., Ltd. Regulatory RinuaGene's HPV Therapeutic mRNA Vaccine Received FDA IND Clearance rinuagene.com ↗
On October 27, 2023 , RinuaGene Biotechnology Co., Ltd. (hereinafter referred to as "RinuaGene") announced that it has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for its proprietary HPV-related therapeutic mRNA vaccine, RG002.

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RG002 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06273553 ↗
Modality Messenger RNA (mRNA) “RG002 Injection (an mRNA Therapeutic Vaccine)” NCT06273553 ↗
Route Intramuscular “administered intramuscularly” NCT06273553 ↗